Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(2); doi: 10.25236/AJMHS.2023.040204.

Research progress in targeting liver cancer stem cells for the treatment of liver cancer


Shen Huihui, Huang Feng

Corresponding Author:
Huang Feng

Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China


CSCs (tumour stem cells) have been shown to be resistant to conventional chemotherapy or irradiation, and surviving CSCs can re-proliferate and lead to tumour recurrenc and Metastasis under suitable conditions due to their strong self-renewal and multiple differentiation functions. The development of metastasis, recurrence and drug resistance caused by CSCs is now considered to be a major cause of treatment failure and patient death inmalignancies[1] .Therefore,direct targeting of LCSCs (hepatocellular carcinoma stem cells) is a new strategy for the treatment of hepatocellular carcinoma. Over the years, as research on LCSCs continues, therapies targeting LCSCs have been found to have great potential in the clinical management and prognosis of hepatocellular carcinoma. This article reviews the specific application of liver cancer stem cell markers interacting with relevant signalling pathways in the treatment of hepatocellular carcinoma.


Liver cancer stem cells; Molecular signaling pathways; Targeted therapy

Cite This Paper

Shen Huihui, Huang Feng. Research progress in targeting liver cancer stem cells for the treatment of liver cancer. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 2: 19-23. https://doi.org/10.25236/AJMHS.2023.040204.


[1] Li Ya. Targeted intervention of STAT3 signaling pathway to induce immunogenic death in hepatocellular carcinoma cells and inhibit tumor stem cell properties[D]. Shandong University,2021.

[2] Liu,L; Borl ak,J. Advances in Liver Cancer Stem Cell Isolation and their Characterization.[J].Stem Cell Rev Rep.2021,17(4):1215-1238.

[3] Sakunrangsit N, Ketchart W. Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer. Pharmacol Res. 2019 Dec;150:104517.

[4] Yamashita T, Budhu A, Forgues M, et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma[J]. Cancer Res, 2007, 67(22):10831-10839.

[5] Ma S, Lee T K, Zheng B J, et al. CD133 + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt / PKB survival pathway [J]. Oncogene, 2008, 27(12):1749-1758.

[6] Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells[J]. J Clin Invest,2010,120(9):3326-3339.

[7] Zhang N, Bai Suhang, Zhang Fuhan, et al. Advances in the study of molecular markers and stemness maintenance mechanism of hepatocellular carcinoma stem cells[J]. Journal of Biological Engineering, 2021, 37(8):2719-2736.

[8] Li Y, Han Q, Zhao H, et al. Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma[J]. Frontiers in Pharmacology,2020,11.

[9] Smith LM, Nesterova A, Ryan MC, et al: CD133/prominin-1 is a potential thera- peutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100  109, 2008 .

[10] Lang J, Lan X, Liu Y, et al: Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human coolorectal cancer xenografts. Nucl Med Biol,2015,42:505-512.

[11] Ma P F, Yang W J, Zhu S S, Zhang S B, Zheng Y W, Zhang X F. Inhibitory effect of T42 peptide on the malignant phenotype of CD133-positive hepatocellular carcinoma stem cells[J]. Chinese Journal of Experimental Surgery,2021,38(1):67-70.

[12] Song,Y; Kim,IK; Choi,I; et al. Oxytetracycline have the therapeutic efficiency in CD133+ HCC population through suppression CD133 expression by decreasing of protein stability of CD133.[J].Sci Rep. 2018,8(1):16100.

[13] Song Y, Park I S ,J Kim, et al. Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133+ HCC[J].Chemico-Biological Interactions,2019,309(Suppl 3).

[14] Christ,B; Stock,P; Dollinger, MM; CD13:Waving the flag for a novel cancer stem cell target.[J]. Hepatology. 2011, 53(4):1388-90.

[15] Haraguchi N, Ishii H, Mimori K,et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010, 120: 3326-3339.

[16] Zhang,K; Chen,W; Zhang,Y;et al. An anti-human CD13 monoclonal antibody that suppresses the suppressive function of Treg cells.[J]. Monoclon Antib Immunodiagn Immunother. 2013,32(1):16-20.

[17] Lu JW, Chang JG, Yeh KT, et al: Overexpression of Thy1/CD90 in human hepatocellular carci- noma is associated with HBV infection and poor prognosis. Acta Histochem , 2011, 113: 833-838.

[18] Yang,R; An,LY; Miao,QF; et al. Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes .[J]. Oncotarget.2016,7(24):35894-35916.

[19] Mima K, Okabe H, Ishimoto T, et al:CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocel- lular carcinoma. Cancer Res 72: 3414-3423, 2012.

[20] Kimura O, Takahashi T, Ishii N, et al: Characterization of the epithelial cell adhesion molecule (EpCAM) + cell population in hepatocellular carcinoma cell lines. Cancer Sci 101:2145-2155,2010.

[21] Zhang S, Wu CC, Fecteau JF, et al: Targeting chronic lymphocytic leukemia cells with a humanized monoclonal anti--body specific forCD44.Proc Natl Acad Sci USA 110:6127-6132, 2013.

[22] Park HY, Lee KJ, Lee SJ. Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. Mol Biotechnol 51: 212- 220, 2012.

[23] Shen,C; Ka,SO; Kim,SJ; et al. Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK.[J]. Tumour Biol. 2016,37(8):11199-208.

[24] Ching RHH, Sze KMF, Lau EYT, et al. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STA T3/Nanog signaling pathway[J]. Oncotarget, 2017, 8(14):23507-23516.

[25] Nowell PC. The clonal evolution of tumor cell populations. Science. 1976 Oct 1;194(4260):23-8.

[26] Dolle L, Theise ND, Schmelzer E, et al. EpCAM and the biology of hepatic stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol, 2015,308(4) :G233-250 .

[27] Yamashita T, Ji J, Budhu A, et al. EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor- Initiating Cells With Stem/Progenitor Cell Features[J]. Gastroenterology, 2009,136(3):1012-1024 .

[28] Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem progenitor cell features. Gastroenterology, 2009, 136(3):1012-1024.

[29] Ishiguro, K; Yan, IK; Lewis-Tuffin, L; et al. Targeting Liver Cancer Stem Cells Using Engineered Biological Nanoparticles for the Treatment of Hepatocellular Cancer.[J]. Hepatol Commun.2020,4(2): 298-313.